FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

81796137 ABSTRACT Compounds represented by formula (I) N-oxides thereof, pharmaceutically acceptable salts or solvates thereof, or glucuronide derivatives thereof, or co-crystals thereof, R3 R2 R5a / ____________________________________ ( R5b R1 // N z / R4 R6 _______________________________ X Y (I)...

Full description

Saved in:
Bibliographic Details
Main Authors VAN HOUTVIN, NATHALIE, DELIGNY, MICHAEL, SABNIS, YOGESH ANIL, MAC COSS, MALCOLM, HEER, JAG PAUL, JACKSON, VICTORIA ELIZABETH, BROWN, JULIEN ALISTAIR, ZHU, ZHAONING, SWINNEN, DOMINIQUE LOUIS LEON, ALEXANDER, RIKKI PETER, JADOT, SOPHIE, KROEPLIEN, BORIS
Format Patent
LanguageEnglish
French
Published 19.07.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:81796137 ABSTRACT Compounds represented by formula (I) N-oxides thereof, pharmaceutically acceptable salts or solvates thereof, or glucuronide derivatives thereof, or co-crystals thereof, R3 R2 R5a / ____________________________________ ( R5b R1 // N z / R4 R6 _______________________________ X Y (I) ' in particular dihydro-1H-pyrano[4',3':4,5limidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-cldipyridine, dihydro-1H-pyrano[3',4':4,5limidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,51imidazo[1,2-a1pyridine, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. Date Recue/Date Received 2021-09-22 La présente invention concerne une série de dérivés d'imidazole tricyliques fusionnés substitués, en particulier la dihydro- 1H-pyrano[4',3':4,5]imidazo[1,2-a]pyridine, la 1,2,3,4-tétrahydroimidazo[1,2-a:5,4- c']dipyridine, la dihydro-1H-pyrano[3',4':4,5]imidazo[1,2-a]pyridine et la tétrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine et leurs analogues, qui sont des modulateurs puissants de l'activité du TNFa humain, et offrent en conséquence des avantages dans le traitement et/ou la prévention de diverses affections chez l'homme, notamment les maladies autoimmunes et inflammatoires ; les maladies neurologiques et neurodégénératives ; les troubles de la douleur et nociceptifs ; les maladies cardiovasculaires ; les troubles métaboliques ; les maladies oculaires ; et les maladies oncologiques.
Bibliography:Application Number: CA20142932057